Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 22.75
Day High 24.44
Open:24.01
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
- BusinessWire - Tue Feb 25, 5:30AM CST
BusinessWire - CMTX
Tue Feb 25, 5:30AM CST
--- Recruited four seasoned executives with expertise across critical commercial functions -
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Common Shares
- BusinessWire - Thu Dec 12, 8:26AM CST
BusinessWire - CMTX
Thu Dec 12, 8:26AM CST
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters' option to purchase additional common shares (the "Offering"). The shares were sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are approximately US$191.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Aurinia Prices US$166.7 Million Public Offering of Common Shares
- BusinessWire - Mon Dec 9, 8:00PM CST
BusinessWire - CMTX
Mon Dec 9, 8:00PM CST
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165 common shares (the "Offering"). The shares are being sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are expected to be approximately US$166.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares are being offered by the Company. The Offering is expected to close on or about December 12, 2019, subject to the satisfaction of customary closing conditions.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 22.70 +5.64% increase
on 01/30/20
Period Open:24.22
Price movement based on the high, low and last over the given period.
27.10 -11.51% decrease
on 02/21/20
-0.24 (-0.99%) decrease
since 01/27/20
3-Month 9.31 +157.57% increase
on 11/28/19
Period Open:9.62
Price movement based on the high, low and last over the given period.
28.59 -16.12% decrease
on 12/27/19
+14.36 (+149.27%) increase
since 11/27/19
52-Week 4.70 +410.21% increase
on 10/10/19
Period Open:9.34
Price movement based on the high, low and last over the given period.
28.59 -16.12% decrease
on 12/27/19
+14.64 (+156.75%) increase
since 02/27/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies